PTO/SB/08a (01-10)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(**Not for submission under 37 CFR 1.99)**

Application Number	10589410
Filing Date	2007-06-04
First Named Inventor	Valentina Molteni
Art Unit	1621
Examiner Name	Zucker, Paul A.
Attorney Docket Number	PAT033827-US-PCT

U.S.PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code[1]	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	5110348		1992-05-05	Hopwood	

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS

Examiner Initial*	Cite No	Publication Number	Kind Code[1]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number[3]	Country Code[2] i	Kind Code[4]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T[5]
	1	DE 1185194	DE		1965-01-14	Nippon Shinyaku Co. Ltd.		☐
	2	EP 134750A1	EP		2003-09-03	Yamanouchi		☐
	3	JP 11001456A	JP		1999-01-06	Ohtsuka		☐

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	10589410
	Filing Date	2007-06-04
	First Named Inventor	Valentina Molteni
	Art Unit	1621
	Examiner Name	Zucker, Paul A.
	Attorney Docket Number	PAT033827-US-PCT

	4	JP 07258224A	JP			Daiichi Seiyaku		☐
	5	JP 56083458A	JP			Hodagaya Chem.		☐
	6	CH 516523A	CH			Sogespar		☐
	7	GB 1236091A	GB			Sogespar		☐

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T[5]
	1	EVANS et al., "Some substituted phenylalkanoic acids and N-substituted malonailic, succinanillic, and anilinoalkanoic acids as potential antiinflammatory agents.", Journal of Medicinal Chemistry, Vol. 12, No. 6, pages 1006-1010, 1969	☐
	2	LARIZZA A., "N-aryl-N-aroylamino acid derivatives.", Journal of Medicinal Chemistry, Vol. 13, No. 5, pages 1019-1020, 1970	☐
	3	CAO et al., "Antidiabetic Action of a Liver X Receptor Agonist Mediated By Inhibition of Hepatic Gluconeogenesis", Journal of Biological Chemistry, Vol. 278, pages 1131-1136, 2003	☐
	4	CAO et al., "Liver X Receptors as Potential Therapeutic Targets for Multiple Diseases", Drug News Perspect., Vol. 17, pages 35-41, 2004	☐
	5	CHIN et al., "Miniaturization of Cell-Based b-Lactamase-Dependent FRET Assays to Ultra-High Throughput Formats to Identify Agonists of Human Liver X Receptors", Assay and Drug Development Technologies, Vol. 1, pages 777-787, 2003	☐

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	10589410
	Filing Date	2007-06-04
	First Named Inventor	Valentina Molteni
	Art Unit	1621
	Examiner Name	Zucker, Paul A.
	Attorney Docket Number	PAT033827-US-PCT

	6	COLLINS et al., "Identification of a Nonsteroidal Liver X Receptor Agonist through Parallel Array Synthesis of Tertiary Amines", Journal of Medicinal Chemistry, Vol. 45, pages 1963-1966, 2002	☐
	7	FOWLER et al., "Liver X Receptor Activators Display Anti-Inflammatory Activity in Irritant and Allergic Contact Dermatitis Models: Liver-X-Receptor-Specific Inhibition of Inflammation and Primary Cytokine Production", J Invest Dermatol., Vol 120, pages 246-255, 2003	☐
	8	JAYE, MICHEAL, "LXR agonists for the treatment of atherosclerosis", Current Opinion in Investigational Drugs, Vol. 4, pages 1053-1058, 2003	☐
	9	JOSEPH et al., "Synthetic LXR ligand inhibits the development of atherosclerosis in mice", PNAS, Vol. 99, pages 7604-7609, 2002	☐
	10	JOSEPG et al., "Reciprocal regulation of inflammation and lipid metabolism by liver X receptors", Nature Medicine, Vol. 9, pages 213-219, 2003	☐
	11	JOSEPH et al., "LXRs: new therapeutic targets in atherosclerosis?", Current Opinion in Pharmacology, Vol. 3, pages 192–197, 2003	☐
	12	LAFITTE et al., "Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue", PNAS, Vol. 100, pages 5419-5424, 2003	☐
	13	LEHMANN et al., "Activation of the Nuclear Receptor LXR by Oxysterols Defines a New Hormone Response Pathway", Journal of Biological Chemistry, Vol. 272, pages 3137-3140, 1997	☐
	14	REPA et al., "Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta", GENES & DEVELOPMENT, Vol. 14, pages 2819–2830, 2000	☐
	15	SCHULTZ et al., "Role of LXRs in control of lipogenesis", GENES & DEVELOPMENT, Vol. 14, pages 2831–2838, 2000	☐
	16	SPENCER et al., "Pharmacophore Analysis of the Nuclear Oxysterol Receptor LXRalpha", Journal of Medicinal Chemistry, Vol. 44, pages 886-897, 2001	☐

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (**Not for submission under 37 CFR 1.99)**		
	Application Number	10589410
	Filing Date	2007-06-04
	First Named Inventor	Valentina Molteni
	Art Unit	1621
	Examiner Name	Zucker, Paul A.
	Attorney Docket Number	PAT033827-US-PCT

	17	TANGIRALLA et al., "Identification of macrophage liver X receptors as inhibitors of atherosclerosis", PNAS, Vol. 99, pages 11896-11901, 2002	☐
	18	TERASAKA et al., "T-0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor-deficient mice", FEBS Letters, Vol. 536, pages 6-11, 2003	☐
	19	TONTONOZ et al., "Liver X Receptor Signaling Pathways in Cardiovascular Disease", Mol. Endocrinol., Vol. 17, pages 985–993, 2003	☐

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. [2] Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). [3] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [4] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [5] Applicant is to place a check mark here if English language translation is attached.